In this week’s Xtalks Life Science podcast episode, Ayesha and the editorial team spoke with Dr. Bastiaan Driehuys, Founder and Chief Technology Officer at Polarean Imaging. Polarean is a medical imaging company focused on improving the state of lung imaging. The company recently received FDA approval for its drug device combination product, Xenoview. Xenoview is a hyperpolarized contrast agent, prepared from the Xenon 129 Gas Blend, that is indicated for use with MRI to evaluate lung ventilation in adults and pediatric patients 12 years of age and older. Tune into the episode to learn more about the FDA approval of Xenoview, including the journey to its approval. Hear about Dr. Driehuys’ extensive research career developing hyperpolarized Xenon 129 as an MRI contrast agent and how that led him to co-found Polarean with the goal of improving the state of lung imaging.For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured